GlassScriptPhysician profile
Mark Jeffrey Klafter
NPI 1730161639
$247,403.05
in general payments reported to CMS, 2019-2025
73 companies · $33K in 2025
The $33K reported for 2025 was more than what 95% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49K · 2020: $23K · 2021: $26K · 2022: $23K · 2023: $57K · 2024: $36K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $93K · Food and Beverage: $16K · Travel and Lodging: $12K · Consulting Fee: $4,500 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $92,637.50 |
| Food and Beverage | $16,445.57 |
| Travel and Lodging | $12,445.79 |
| Consulting Fee | $4,500.00 |
| Education | $117.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $80,283.00 | 2019-2025 | Nuplazid, Daybue |
| Abbvie INC. | $55,475.10 | 2019-2025 | |
| Allergan, INC. | $39,756.08 | 2019-2022 | |
| Acorda Therapeutics, INC | $31,687.46 | 2019-2024 | Inbrija, Ampyra |
| Teva Pharmaceuticals USA, INC. | $17,985.38 | 2019-2023 | Austedo, Austedo Xr |
| Genzyme Corporation | $1,929.02 | 2019-2025 | |
| Biogen, INC. | $1,355.45 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Emd Serono, INC. | $1,094.85 | 2019-2025 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $990.15 | 2019-2025 | |
| Ucb, INC. | $963.28 | 2019-2025 | Rystiggo |
| Amgen INC. | $939.02 | 2019-2025 | Uplizna |
| Alexion Pharmaceuticals, INC. | $805.90 | 2019-2025 | Ultomiris |
| Jazz Pharmaceuticals INC. | $801.53 | 2020-2025 | Xywav |
| Lilly USA, LLC | $792.26 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Argenx US, INC. | $745.71 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Klafter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.